Podcast appearances and mentions of Chris Sloan

Curious about how to make money in land investing? In this episode, we sit down with Chris Sloan as he shares his daily routine, deal-finding strategies, and a breakdown of a $34,000 profit land deal. Learn why consistency is key, how to put your name out there, and why hearing "no" can be a good thing. If you're looking to build a successful land investing business, this episode is packed with actionable insights! Don't just listen—take action! Start applying these land investing strategies today and turn your next deal into a success. Visit the The Landsharks Program for more.---------Show notes:(0:50) Beginning of today's episode(3:35) Chris' daily/weekly routine and managing his land investing business(5:17) How does he find his land deals?(7:05) A deal breakdown of $34,000 gross profit(11:17) Be consistent and put your name out there(12:50) The hidden value of rejection----------Resources:Sell My House FastGo for NoContact Chris at: (858) 461-8067 or Email him at: chris@thenationallandcompany.comLand Sharks Land Offer LettersTo speak with Brent or one of our other expert coaches call (281) 835-4201 or schedule your free discovery call here to learn about our mentorship programs and become part of the TribeGo to Wholesalingincgroup.com to become part of one of the fastest growing Facebook communities in the Wholesaling space. Get all of your burning Wholesaling questions answered, gain access to JV partnerships, and connect with other "success minded" Rhinos in the community.It's 100% free to join. The opportunities in this community are endless, what are you waiting for?

This week: Guest Co-Host Chris Sloan with info on BermudAir; Several see Spirit as attractive; British Airways & Virgin participate in love triangle; Las Vegas "Supplemental" Airport in the works; American adds to BOS-LGA; Tom Doxey to Southwest as CFO; DCA incident news update; Boeing steps up deliveries; Listener comments on open skies in the new administration, post DCA crash reactions. Next week: The Delta crash and SWA layoffs.

It's cold outside and that calls for some hot birding takes. We've collected some for another edition of Take It or Leave It, the discussion panel for the most opinionated birders. This time we welcome Chris Sloan and Martha Harbison to talk about mentorship in the internet age, whether birders underappreciate Canada, and what would it take to get back to the old rarity phone trees.  Also, the ABA is not the only organization with a Bird of the Year in 2025. Let's celebrate some more! Subscribe to the podcast at Apple Podcasts, Spotify, or wherever you get your podcasts and please leave a rating or a review if you are so inclined! We appreciate it!    

Bamboo fly rods have been around since the early 1800s and still play an important role in fly fishing. There are many ways to build a bamboo fly rod and Sam Johnson and Chris Sloan have their own unique method. Join us and learn about Sam's eight-step process to building a better rod faster. Whether you're just thinking about building your first rod or are an experienced rod builder you're sure to learn a few tips and techniques in this in-depth show.

This week: Chris Sloan flies Iberia and reports on the A321 XLR inaugural flight; Plus: Facts, context, and perspective on the Spirit prepackaged bankruptcy plan, what Ben would say, and what happens next; Gunshots hit multiple aircraft; Court rules Oakland is not San Francisco.

Chris tells Charley about his recent trip to see the rare Zino's Petrel on the island of Madeira. Zino's Petrel recording courtesy of Quentin Guibert, XC806563. Accessible at www.xeno-canto.org/806563. License Creative Commons Attribution-NonCommercial-ShareAlike 4.0 If you wish to support this podcast, please visit our Patreon page at: https://www.patreon.com/naturallyadventurous?fan_landing=true Feel free to contact us at: ken.behrens@gmail.com or cfchesse@gmail.com Naturally Adventurous Podcast

This week: An announcement from Ben Baldanza; Plus, never before told Ben stories as Scott McCartney welcomes back Seth Kaplan, Chris Chiames, and Chris Sloan as guests to salute Ben; News: Air & Cruise travel demand; Aircraft delivery delays; Capacity discussion; Delta reliability; Listener Q: What would you do if you were CEO at SWA?

Having fun isn’t hard when you’ve got a library card! For this month’s Your Hometown, we focus on Bensenville. In doing our part in helping educate our listeners, John is joined by Chris Sloan, the director of the Bensenville Community Public Library. Chris expounds on some of the events taking place at the library over […]

This week: Chris Sloan: In depth on Hawaiian Airlines; Also: The reality of the London-Singapore flight story; Adding clarity to Frontier's pricing/change fee policy; Remembering Norm Mineta; Listener input: Calling out Allegiant on a "rip-off" ticketing fee, Expedia's multiple brands. Bonus interview content from AFA available at https://airlinesconfidential.com/afa2024

This week: Chris Sloan on The Airchive; Initial thoughts on the Alaska-Hawaiian deal; Skift story on increased adventure travel due to weight loss: NY Times reports on serious FAA issues; Listener Q: Takeaways from other international agencies? What is the role of a CTO in undertaking change?

This week: Jeff Tolkin, Co-CEO, World Travel Holdings, Michael Whitaker confirmed as FAA Administrator, Spirit blames discounted fares for Q3 loss; Southwest makes significant schedule changes; The Alaska off-duty pilot incident; Qatar Airways' "Chief" resigns; Listener Q's: Industry employment potential & Ben's reaction to Chris Sloan's Air Inuit report, and a term paper help request.

This week: Chris Sloan takes us aboard Air Inuit; Also: Increasing industry financial pressure; Airlines stocks taking a beating; Ed Bastian's SkyMiles modifications; Listener Q re: DOT Air Travel Consumer Report & regional carrier on time performance.

On this episode of AvTalk, we chat with curator of theAirchive.net, Chris Sloan. United Airlines adds more aircraft to its order book, SAS will say hello to Air France+KLM and goodbye to Star Alliance, and Qantas is in more hot water thanks to an IT malfunction. This week's highlights Air France+KLM will become a major […] The post AvTalk Episode 236: Into the Airchive! appeared first on Flightradar24 Blog.

This week: Chris Sloan reports on the unique history of Braniff; Plus: Impact of shutdown on an already unacceptable FAA understaffing situation; Southwest's Bob Jordan goes to Denver; NYT reporter David Brooks' $78 Newark lunch; Listener topics: Odds of SWA pulling out of Oakland, "Slots" at EWR.

Season 3 of the Midtown Madness Podcast is brought to you by Two Men and a Garden! That's right they are fueling this podcast with not only delicious pickles, but salsas and most recently Harissa sauce. They are the real deal! Their products are delicious and more importantly local to St. Louis. You can pick up their many products at any local grocery stores or online where they ship nationwide!

There are two facets of the Humira biosimilar market and launch that Anna Hyde, my guest in this healthcare podcast, talks about. One is market dynamics. The second is provider and patient confidence. These two concepts are tangled up together and cannot be separated. But let me back up a sec and explain, although Anna Hyde covers this really well and offers context in the interview that follows. So, first facet: market dynamics. This means fostering competition so the price of something goes down. That is the basis of capitalism. After all, you need competition to get in there and try to steal customers from each other by scuffling over price. In 2023, there's supposed to be 12 biosimilar products for Humira that come out. So, we'll see scuffling and lower prices? Hmmm … maybe not so fast. Second intertwined facet: provider and patient confidence that the biosimilars are as effective and have similar side effects (ie, there is confidence that the biosimilars are actually, for reals, interchangeable with the so-called reference product [ie, Humira]). Bottom line, if providers and patients are not confident in the biosimilar, then no prescribing is gonna happen. Couple those provider and patient clinical concerns with a concern about manufacturer financial assistance. If providers and patients are worried that the out of pocket will be too high and the biosimilar manufacturers are not gonna offer any financial assistance, then, again, no confidence, no prescribing. So, if either or both of these concerns is present and the no prescribing is the result, this vote of no confidence means there will be no or limited uptake of the biosimilars. And what does the no uptake mean? It means no lower prices. Having competition per se isn't gonna lower the prices because the monopoly remains the monopoly. It's having uptake of the competition that will erode the monopoly. It's having patients who are willing to migrate to the competitive products. And this is pretty vital here because, right now, there's a lot of cynicism out there about this biosimilar launch and that it is not really going to lower the cost of these drugs much for plan sponsors. And, you know, is anyone terribly surprised given it sure seems like AbbVie, who is the manufacturer of Humira, still has a lot of dominance in the market? “How do they still dominate the market even though their patent thicket years are officially over?” you might ask. For one, they have payers over a barrel because members who need the Humira molecule are still 100% on Humira. Thus, AbbVie can still demand contract terms for Humira like the demand that Humira has the lowest patient out of pocket for patients or has an equivalent out of pocket to any formulary biosimilars. And this is currently going on. (Listen to the show with Dea Belazi [Encore! EP293] for why that matters so much from a market dynamics standpoint.) A second reason why Humira can still dominate the market even after their patent expiry is that plans and PBMs (pharmacy benefit managers) are, as Chris Sloan put it in episode 216, “addicted to rebates”; and Humira offers big rebates, which they will likely increase to match any pricing pressure from biosimilars. Here's a quote from the Goodroot white paper on this Humira biosimilars business, which is otherwise known as the “hottest topic in pharmacy.” Goodroot says, “Given the cost-rebate power play—and the monetary loss that PBM[s] ... assume when rebate dollars are removed—we don't anticipate any significant shift to biosimilars or cost savings as Humira biosimilars become available.” So ... doom? Not so fast. The Goodroot white paper continues with this next quote, and this is exactly what Anna Hyde also talks about and gives some historical proof points for, actually. Goodroot says, “There may be a tipping point in biosimilar pricing where the net cost differential will be significant enough to force [plan sponsors/payers] to make their PBMs prefer the biosimilars.” And then the white paper says exactly what Anna Hyde also says, and which I reiterated moments ago: “[For this tipping point to happen], this significantly lower net price must be coupled with a significant shift in market share to make up for the loss of [the] Humira rebate.” Let me translate that: Provider and patient uptake has to happen here for the prices in this therapeutic category to go down across the board to meet that tipping point. Anna Hyde gives some great advice, and this advice is all summed up on a landing page on the Arthritis Foundation Web site. This landing page includes advice for health plans, and a big part of that advice is to communicate clearly with physicians and other providers and also, essentially, with members and patients. Patients cannot find out that they just got switched to a biosimilar when they get a different box in the mail with a different med with a different delivery device that they have never seen before with a needle that's gonna pop out from some mystery location. This is a Fail (with a capital F) for all kinds of reasons that could ultimately undermine the whole Operation Biosimilar some plan is trying to pull off in an effort to try to lower prices to a tipping point so everybody can save money. There is evidence to suggest that, over time, biosimilars can reduce costs—maybe a lot. But for this to happen, it's gonna take really a thoughtful approach filled with bidirectional communication with providers and patients. Cannot forget this step. If everybody's on the same page, it may take a bit; but market dynamics will eventually kick in and prices will go down across the board. Everybody wins. My guest today, Anna Hyde, is VP of advocacy and access over at the Arthritis Foundation. She's a federal lobbyist and helps advance legislation and policies so patients can have better access to affordable medications and specialists. If you're looking for more insights into topics we discuss today, I suggest listening to the encore with Dea Belazi (Encore! EP293) about co-pay assistance programs; the show with Chris Sloan (EP216) about how plans get addicted to rebates; and if you really want to take a deep dive, check out this playlist of eight specialty pharmacy episodes. Listen to all of these shows and you will know more than 99% of healthcare insiders about who is kicking back to who and where the dollar is going in the specialty pharmacy market—which is essential background information if you're planning to evaluate the impact or the potential impact of these biosimilars.   You can learn more by emailing Anna at ahyde@arthritis.org and connect with her on LinkedIn.    Anna Hyde is the vice president of advocacy and access at the Arthritis Foundation. She oversees both the federal and state legislative programs, in addition to grassroots engagement. Her focus is to raise the visibility of arthritis as a public health priority; build support for federal and state legislation that ensures access to affordable, high-quality healthcare; and enhance patient engagement in the policy-making process. Anna previously served as senior director of advocacy and access, managing the federal affairs portfolio and overseeing the state advocacy team. Prior to joining the Arthritis Foundation in 2014, Anna worked as senior manager for federal affairs at the American Congress of Obstetricians and Gynecologists, where she managed a portfolio of issues, including appropriations, physician workforce, and health IT. She began her health policy career as a Congressional Fellow for Energy and Commerce Committee members, where she drafted legislation and staffed committee activities. Anna received a bachelor's degree in history from Southern Methodist University and taught junior high and high school history before moving to Washington, DC, in 2007 to pursue a master's degree in political science from American University.   07:38 What does a successful biosimilar market depend on? 09:07 Why does uptake seem to reduce prices? 10:24 How important is the relationship with the healthcare provider? 11:35 Where are we in getting these biosimilars to market? 13:02 Are there differences between the reference product and biosimilars? 19:26 Why does the way you approach the patient matter? 22:36 Why do providers feel like they don't have a lot of agency in the biosimilar conversation? 24:50 What should health plans be thinking if they want to go down the biosimilar path? 27:36 “Our goal is to keep a feedback loop such that no patient falls through the cracks.” 28:21 What is the “nocebo” effect? 31:27 What is Anna's advice to plan sponsors on communicating with providers and plan sponsors?   You can learn more by emailing Anna at ahyde@arthritis.org and connect with her on LinkedIn.   Anna Hyde of @ArthritisFdn discusses the #humira #biosimilar market and launch on our #healthcarepodcast. #healthcare #podcast   Recent past interviews: Click a guest's name for their latest RHV episode! Dea Belazi (Encore! EP293), Brennan Bilberry, Dr Vikas Saini and Judith Garber, David Muhlestein, Nikhil Krishnan (Encore! EP355), Emily Kagan Trenchard, Dr Scott Conard, Gloria Sachdev and Chris Skisak, Mike Thompson, Dr Rishi Wadhera (Encore! EP326)  

What does the real estate market look like in Grantsville? Chris Sloan, Broker and Owner of Group 1 Real Estate, joins the show to talk about the state's $20K first-time homebuyer assistance program and give examples of listings he's aware of.See omnystudio.com/listener for privacy information.

This week: Kevin P. Healy, President, Campbell-Hill Aviation Group; Also: 747 Trivia with Chris Sloan vs Ben & Scott. Do you know the answers? President Biden wants "junk fees" reigned in; Norway airline Flyr shuts down & files for bankruptcy; Jeff Shane provides a 747 legacy clarification.

This week: Anne Correa, SVP, Airline & Airport Services, mba Aviation; Chris Sloan reports on Southwest Airlines' Media Day; Listener feedback on the Hertz interview and the Kirby vs Biffle viewpoint discussion. Shout-outs.

10/30/2022 Speakers: Anthony Braswell and Chris Sloan

This week: Chris Sloan on Routes World 2022 Las Vegas Conference; United, American, Alaska, strong Q2 results but what about costs? Wizz Air expands to Middle East; Hawaiian Airlines & Amazon team up; Listen Q: Are the more experienced regional pilots getting a fair shot at mainline jobs? Is SWA open seating policy a security risk? Shout-outs

This week: Chris Sloan: Huge Expansion at Orlando International (MCO); Airline performance during Ira; BOOM shops for an engine; Listener Q: Economics of Delta insourcing M&R; Ticket cost difference between European and US credit card? Air France Paris-Boston booking non-notification: Fine or Whine?

Last week's show was an encore episode with Dr. Aaron Mitchell (Encore! EP282), and we talked about buy and bill. To continue our exploration of specialty pharmacy intrigue, let's talk about so-called “bagging.” I wanted to get an overview of all of the different kinds of specialty pharmacy bagging. Bagging is a big deal. If you have anything to do with trying to control pharmacy costs or the clinical outcomes of specialty pharmacy patients, you too are going to want to understand what's going on here with bagging. I was thrilled to have a chance to chat with Keith Hartman, who is my guest in this healthcare podcast. He is the CEO of ContinuumRx. He's a pharmacist by education and has been in the pharmacy space for over 25 years now, touching just about every aspect of pharmacy from retail operations to long-term care and now, most recently, home infusion. This makes him an ideal person to chat with about this topic. And FYI, it was not easy to find someone to do so to clearly see the actions and reactions going on here because that's what this is all about: actions and reactions—how any self-respecting market distortion is going to cause a cascade of equal and opposite market distortions. So, let's cruise through the whole infused/injected specialty pharmacy historical play-by-play, shall we? It's like a “Who's on First?” routine—except very, very not funny. So, here we go. This is, of course, the semi-reductive abridged version; but let's do this thing. Once upon a time, the bagging story starts in ye olden days, meaning more than ten years ago, before specialty pharmacy drugs really became the massive profit centers for any party who can manage to get their fingers in the specialty pharmacy cookie jar. In these ancient and halcyon times, brown bagging was kind of a modus operandi. Don't forget, we're talking about infused or injectable drugs here, especially ones that need to be infused or injected in the provider's office. So, brown bagging means and meant when a specialty pharmacy drug is shipped directly to a patient, or a patient goes and picks up the specialty pharmacy drug at the pharmacy. Doc takes out prescription pad (this is in ye olden days, remember) and writes out the Rx. Patient picks up the drug from the pharmacy, which may be handed to them in a brown bag. Get it? But then they take that “brown bag,” as it were, to their doctor's office. The doctor takes the drug out of the brown bag and infuses or injects it. I say doctor's office because many times, in the olden days, that's where this went down. And this brown bagging had some issues, for sure; but specialty pharmacy drugs really weren't all that big of a thing either dollar-wise or frequency-wise. At some point in our story here, pharma manufacturers start seeing just exactly how much money the market will bear for specialty pharmacy drugs, and the prices of these specialty drugs go through the roof. At the same time, for a bunch of reasons I actually discussed with Dr. Bruce Rector (EP300), a whole bunch of these specialty pharmacy drugs start hitting the market all at once. So, these drugs have skyrocketing prices—and there's lots of them.   At that point, some (certainly not all, but enough) CFOs at provider organizations were like—wowza, epiphany, light bulb moment—there's a lot of money that can be made here because buy and bill. In buy and bill, which I talked about last week with Dr. Aaron Mitchell, provider organizations get reimbursed the cost of the drug plus some percentage when they administer it—meaning the more expensive the drug, the more money a provider can make because a percentage of a bigger number is, of course, a bigger number. Add to that a party-sized container of other provider shenanigans to maximize revenue on specialty pharmacy patients—and that revenue got bigger every single year. A recent report just came out that, on average, for oncology drugs, some providers are making six times the cost of the drug. Six times the cost of a drug that can cost lots of zeros! Just wow—6x! That's real money. This is winning the lottery every single time a patient needing a specialty drug shows up on your doorstep.   Continuing the tale here, this buy and bill health system extreme greed hits employers in their pocketbooks. And, of course, plan sponsors start desperately seeking relief. Who rides up on a white horse? PBMs (pharmacy benefit managers), of course. PBMs say that they will negotiate with drug companies and buy the drugs on behalf of the plan sponsors for much cheaper. Then they will ship the drugs purchased to the provider organizations. Thus, the plan sponsor only needs to pay providers to administer the drug, not that and some crazy markup on the drug itself. Ladies and gentlemen, white bagging has entered the building. White bagging is when the drug is not shipped directly to the patient à la brown bagging. It is when the drug is shipped to the provider. But wait … there's more to the story than a grand PBM gesture of goodwill. They see how much money the employers are used to paying providers for these drugs and realize that the PBM only needs to come in with a price that's less than that, at least at the beginning. So, over the years, weird stuff starts happening with rebates on the specialty drugs. Listen to the show with Scott Haas (EP365) for more on that. But bottom line, white bagging becomes not exactly a mecca of cost savings. PBMs are, as we all know, not known for their ability to moderate their profitability, after all. At this point in our story, let's just pause to say that provider organizations are very, very, very not happy with this whole white bagging intervention. Not only did a piece of the provider's specialty pharmacy cash cow get snatched by the PBMs, but there are also clinical issues with white bagging that we talk about on the show today. And some of these issues are not BS. Do not get me wrong. They are very real, and I do not want to minimize them. And so, provider organizations start to stand up their own hospital specialty pharmacies because then at least they can get some of the white bagging cha-ching. See what I mean? Plan sponsor, health plan mandates that the drug be filled in a pharmacy, hospital owns the pharmacy or part of the pharmacy … and now they have so-called clear bagging. Clear bagging is when one organization owns the pharmacy and the provider who will administer the drug. Clear bagging solves some of the clinical issues with white bagging, and the hospital also gets to take a cut. I'd be remiss not to mention here that some hospitals have worked very hard on their clear-bagging programs and definitely have tried to improve the quality of service here. You're going to have to listen to the show to hear about gold bagging and also the latest developments in this whole war employers and patients and taxpayers are fighting with PBMs and hospitals who are fighting with each other over who gets the money. Also, the continuing trend of brown bagging, especially as “in the patient's home” gets tagged on the end of lots of care delivery like “in bed” gets tagged on the end of lots of fortune cookies. Next week's show will dig into how exactly some providers are managing to get the up to 6x the cost of specialty pharmacy drugs when Medicare Part B at least says that they're only supposed to get ASP [average sales price] + 6% (ish). I just could not figure out how they were managing to get 6x just given that Medicare Part B rule, but yeah, they are—and we'll learn about that next week. You can learn more at continuumrx.com.   Keith P. Hartman, RPh, is chief executive officer of ContinuumRx and an experienced operating entrepreneur and pharmacy business owner spanning two decades. Keith founded and grew a chain of retail pharmacies, a compounding pharmacy, and two specialty pharmacies along with a long-term care pharmacy. All were built and grown under the guise of operational excellence and produced great results. Some were sold, while others he still owns and provides limited strategic guidance as a member of the board of directors. Keith graduated from the University of the Sciences with a degree in pharmacy. Today he is still involved mentoring future pharmacists and pharmacy owners. 08:09 What kinds of patients and/or drugs is the concept of bagging relevant to? 08:53 What is brown bagging, and what are the issues with it? 10:28 What is white bagging, and how is it different from brown bagging? 11:30 Who are the key players in pharma bagging? 12:25 Why does a PBM want a specialty drug to go through them? 12:49 From the physician's perspective, why is buy and bill ideal? 16:46 How does white bagging impact patient clinical care? 22:12 Encore! EP216 with Chris Sloan. 23:05 What are the two main reasons patients might not continue their therapy? 23:29 “We've got to leave some authority with our prescribers to be able to make a clinical decision of what's best for that … patient.” 24:41 What is clear bagging? 26:51 How does a hospital specialty pharmacy get in network with a PBM? 28:57 What is gold bagging? 30:11 “Outlook really needs to be what's best for the patient.” 32:10 EP337 with Olivia Webb.   You can learn more at continuumrx.com.   Keith Hartman of @continuumrx1 discusses #specialtypharmabagging on our #healthcarepodcast. #healthcare #podcast #pharma #specialtypharma What kinds of patients and/or drugs is the concept of bagging relevant to? Keith Hartman of @continuumrx1 discusses #specialtypharmabagging on our #healthcarepodcast. #healthcare #podcast #pharma #specialtypharma What is brown bagging, and what are the issues with it? Keith Hartman of @continuumrx1 discusses #specialtypharmabagging on our #healthcarepodcast. #healthcare #podcast #pharma #specialtypharma What is white bagging, and how is it different from brown bagging? Keith Hartman of @continuumrx1 discusses #specialtypharmabagging on our #healthcarepodcast. #healthcare #podcast #pharma #specialtypharma Who are the key players in pharma bagging? Keith Hartman of @continuumrx1 discusses #specialtypharmabagging on our #healthcarepodcast. #healthcare #podcast #pharma #specialtypharma Why does a PBM want a specialty drug to go through them? Keith Hartman of @continuumrx1 discusses #specialtypharmabagging on our #healthcarepodcast. #healthcare #podcast #pharma #specialtypharma From the physician's perspective, why is buy and bill ideal? Keith Hartman of @continuumrx1 discusses #specialtypharmabagging on our #healthcarepodcast. #healthcare #podcast #pharma #specialtypharma How does white bagging impact patient clinical care? Keith Hartman of @continuumrx1 discusses #specialtypharmabagging on our #healthcarepodcast. #healthcare #podcast #pharma #specialtypharma What are the two main reasons patients might not continue their therapy? Keith Hartman of @continuumrx1 discusses #specialtypharmabagging on our #healthcarepodcast. #healthcare #podcast #pharma #specialtypharma “We've got to leave some authority with our prescribers to be able to make a clinical decision of what's best for that … patient.” Keith Hartman of @continuumrx1 discusses #specialtypharmabagging on our #healthcarepodcast. #healthcare #podcast #pharma #specialtypharma What is clear bagging? Keith Hartman of @continuumrx1 discusses #specialtypharmabagging on our #healthcarepodcast. #healthcare #podcast #pharma #specialtypharma How does a hospital specialty pharmacy get in network with a PBM? Keith Hartman of @continuumrx1 discusses #specialtypharmabagging on our #healthcarepodcast. #healthcare #podcast #pharma #specialtypharma What is gold bagging? Keith Hartman of @continuumrx1 discusses #specialtypharmabagging on our #healthcarepodcast. #healthcare #podcast #pharma #specialtypharma “Outlook really needs to be what's best for the patient.” Keith Hartman of @continuumrx1 discusses #specialtypharmabagging on our #healthcarepodcast. #healthcare #podcast #pharma #specialtypharma   Recent past interviews: Click a guest's name for their latest RHV episode! Dr Aaron Mitchell (Encore! EP282), Stacey Richter (INBW34), Ashleigh Gunter, Doug Hetherington, Dr Kevin Schulman, Scott Haas, David Muhlestein, David Scheinker, Ali Ucar, Dr Carly Eckert, Jeb Dunkelberger (EP360), Dan O'Neill, Dr Wayne Jenkins, Liliana Petrova, Ge Bai, Nikhil Krishnan, Shawn Rhodes, Pramod John (EP353), Pramod John (EP352), Dr Eric Bricker, Katy Talento, Stacey Richter (INBW33), Stacey Richter (INBW32), Dr Steve Schutzer (Encore! EP294), Lisa Trumble, Jeb Dunkelberger, Dr Ian Tong, Mike Schneider  

This week: Chris Sloan reports on the unique experience of flying in Alaska and quizzes Ben & Chris on Ultra Av Geek trivia; Southwest bullish on business travel; Avianca merges with Viva; Chaos at Amsterdam's Schiphol airport; Frontier's high ancillary revenue; Listener Q: Financial risk to buy a ticket on AA? Complaint involving Spirit & Carnival-Fine or Whine? Shout out to Tuskegee Airman Sgt. Victor Butler for his 100th Birthday.

Join us this morning as we hear from guest preacher Chris Sloan, during which he'll interview his brother Jeff Loree!

Join us this morning as we hear from guest preacher Chris Sloan, during which he'll interview his brother Jeff Loree!

While we have tried to avoid the topic of COVID, today we are diving in! In this episode, we are joined by Chris Sloan, the President and Chief Creative Officer of 2C Creative. As the ultimate AvGeek and an accomplished writer, Chris's CV is quite fascinating. Today, however, he joins us to share his recent experience of a family trip to St. Lucia that went awry due to COVID. Chris explains all the protocols he followed to get to St. Lucia, how he first realized he was having symptoms, and how he tested positive for the virus as part of the COVID procedure to return home. Chris sheds light on how seriously St. Lucia takes COVID, what quarantining in the resort was like for him and his family, the financial implications of his involuntary extended stay, and how he feels about returning to the Caribbean island. Chris may be the first-ever guest on the show who loves American Airlines, and in this discussion, he explains why. You'll also hear about his love of aviation, his role in developing Airways Magazine, and his passion project The Airchive. Before the episode is over, we also share our thoughts on the location of Resorts World in Vegas and the recent changes to MGM Rewards. For all this and more, tune in today!Want to contact us or share something?Email us at:tips@travelzork.com--------------------------------------------Book your next trip with TravelZork Travel!Luxury Hotel Program for Las Vegas and WorldwideBook today:Conrad Las Vegas at Resorts World Las Vegas - Hilton Impresario Program--------------------------------------------Links for episode 124Chris Sloan  Chris Sloan on Twitter  UPDATE: This TPG reader tested positive while on vacation in St Lucia; Here's what happened nextThe Airchive Join The TravelZork Facebook Group - lots of great travel and casino loyalty conversations!--------------------------------------------Support the show! VISIT ZorkOfferwww.zorkoffer.comFoundersCard Membership ProgramSupport the show (https://travelzork.com/travel-deals/usa-miles-points-credit-card-offers/)

Over the holiday season here, we're running some of our favorite episodes from years past. This one is with Mike Schneider, who actually has taken another role since this show was recorded. Other than that, the information that Mike shares during this episode from 2020 is all good. So, let's do this thing. Disclaimer before we get started here: This show is probably a 300-level class in pharmaceutical/PBM relations. If you are tuning in for the first time and you aren't pretty familiar with the role of PBMs, I would go back and listen to, say, episode 241 with Vinay Patel or episode 166 with Tim Thomas from Crystal Clear Rx. OK, now that that's out of the way, if you're still with me, this episode is like a ride on a roller coaster. I talk with Mike Schneider. And we get into, you know, kinda deeply, the what and the why behind the “Big Three” traditional PBMs deciding that now might be a fantastic time to set up GPOs. PBMs are pharmacy benefit managers—there's three huge ones. GPO stands for group purchasing organization. Traditionally, these GPOs have purchased drugs and supplies for hospitals and other providers at, according to their marketing materials, volume discounts. So, the unfolding story here, in a nutshell, is that ESI (Express Scripts) set up a GPO called Ascent in Switzerland. Optum has had an Ireland operation going in full swing for a while. And now we have CVS Caremark setting up a GPO called Zinc. These GPOs are not like normal GPOs working with hospitals, but instead, these GPOs are the entity which is now going to negotiate with pharma companies. In the past, it was the PBM that was negotiating with the pharma company to get rebates. Now it's this GPO entity. “But wait,” you may say. “Wasn't there an executive order the other day requiring PBMs to, for example, pass through all of the rebates that they're collecting to patients?” Indeed, there was. And that rule doesn't say anything about GPOs having to do the same, especially GPOs in, let's just say, Switzerland. It's a tangled web we weave. You can learn more by connecting with Mike on LinkedIn.  Mike Schneider is an experienced healthcare executive with over 20 years of experience in the pharmaceutical manufacturer, pharmacy benefit manager, and payer side of healthcare. He previously spent 9 years at CVS Caremark, where he was a director of industry relations with responsibility for trade strategy development, rebate negotiations, and contract execution for CVS Caremark's own Medicare Part D plans and that of its clients. He held a similar position at Universal American (UA) before it was acquired by CVS Health, where he also negotiated UA's commercial business. Mike has held various sales and market access roles with pharmaceutical manufacturers with increasing responsibility. Before entering healthcare, Mike began his career as a researcher at the Procter & Gamble Company in Cincinnati, where he worked on hair care product formulation development focusing on the key markets of China and Japan, and then moved on to work in drug development. Mike holds a BS degree from the University of Illinois and an MBA from the University of Akron. 02:48 What does a GPO add to a PBM? 05:23 Rebates vs driving more revenue. 10:39 PBMs vs safe harbors. 12:25 The net impact on the commercial side. 14:07 PBMs vs pharmaceutical manufacturers. 14:54 How the “Big Three” PBMs compete with each other, and how employers would choose between them. 15:56 What the net-net is here. 18:06 How PBMs are shifting their models. 20:42 How GPOs may be making things even less transparent. 21:31 “The PBM world as a whole is not very transparent.” 25:00 “One of the biggest beneficiaries of this whole rebate [system] is the government.” 25:46 “The question is, ‘Who's paying those costs?'” 26:02 EP216 with Chris Sloan.27:00 A better way to move money from Pharma to employers and plan sponsors. 28:04 “Put your money where your mouth is.” You can learn more by connecting with Mike on LinkedIn.  Check out our newest #healthcarepodcast with Mike Schneider as he discusses #PBMs and #GPOs. #healthcare #podcast #digitalhealth #healthcarefinance #pharma What does a GPO add to a PBM? Mike Schneider discusses #PBMs and #GPOs. #healthcarepodcast #healthcare #podcast #digitalhealth #healthcarefinance #pharma Rebates vs driving more revenue. Mike Schneider discusses #PBMs and #GPOs. #healthcarepodcast #healthcare #podcast #digitalhealth #healthcarefinance #pharma PBMs vs safe harbors. Mike Schneider discusses #PBMs and #GPOs. #healthcarepodcast #healthcare #podcast #digitalhealth #healthcarefinance #pharma What is the net impact on the commercial side? Mike Schneider discusses #PBMs and #GPOs. #healthcarepodcast #healthcare #podcast #digitalhealth #healthcarefinance #pharma PBMs vs pharmaceutical manufacturers. Mike Schneider discusses #PBMs and #GPOs. #healthcarepodcast #healthcare #podcast #digitalhealth #healthcarefinance #pharma How do the “Big Three” PBMs compete with each other? Mike Schneider discusses #PBMs and #GPOs. #healthcarepodcast #healthcare #podcast #digitalhealth #healthcarefinance #pharma How do #employers choose between the “Big Three” PBMs? Mike Schneider discusses #PBMs and #GPOs. #healthcarepodcast #healthcare #podcast #digitalhealth #healthcarefinance #pharma What's the net-net here? Mike Schneider discusses #PBMs and #GPOs. #healthcarepodcast #healthcare #podcast #digitalhealth #healthcarefinance #pharma How are PBMs shifting their revenue models? Mike Schneider discusses #PBMs and #GPOs. #healthcarepodcast #healthcare #podcast #digitalhealth #healthcarefinance #pharma How are GPOs making things even less transparent? Mike Schneider discusses #PBMs and #GPOs. #healthcarepodcast #healthcare #podcast #digitalhealth #healthcarefinance #pharma “The PBM world as a whole is not very transparent.” Mike Schneider discusses #PBMs and #GPOs. #healthcarepodcast #healthcare #podcast #digitalhealth #healthcarefinance #pharma “One of the biggest beneficiaries of this whole rebate [system] is the government.” Mike Schneider discusses #PBMs and #GPOs. #healthcarepodcast #healthcare #podcast #digitalhealth #healthcarefinance #pharma “The question is, ‘Who's paying those costs?'” Mike Schneider discusses #PBMs and #GPOs. #healthcarepodcast #healthcare #podcast #digitalhealth #healthcarefinance #pharma A better way to move money from Pharma to employers and plan sponsors. Mike Schneider discusses #PBMs and #GPOs. #healthcarepodcast #healthcare #podcast #digitalhealth #healthcarefinance #pharma “Put your money where your mouth is.” Mike Schneider discusses #PBMs and #GPOs. #healthcarepodcast #healthcare #podcast #digitalhealth #healthcarefinance #pharma Recent past interviews: Click a guest's name for their latest RHV episode! Peter Hayes, Paul Simms, Dr Steven Quimby, Dr David Carmouche (EP343), Christin Deacon, Gary Campbell, Kristin Begley, David Contorno (AEE17), David Contorno (EP339), Nikki King, Olivia Webb, Brandon Weber, Stacey Richter (INBW30), Brian Klepper (AEE16), Brian Klepper (EP335), Sunita Desai, Care Plans vs Real World (EP333), Dr Tony DiGioia, Al Lewis, John Marchica, Joe Connolly, Marshall Allen, Andrew Eye, Naomi Fried, Dr Rishi Wadhera, Dr Mai Pham, Nicole Bradberry and Kelly Conroy, Lee Lewis

This week: Chris Sloan reports on first Breeze Airways A220 & it's unusual configuration; American's operational/staffing issues; Avoiding issues at Thanksgiving; What should a CEO do when a Flight Attendant gets punched? How do airlines select what equipment goes where? Fine or Whine? and shout-outs.

Former Billiken guard and Current Rockhurst Men's Basketball Head Coach joins the show to talk about head coaching career so far, his relationship with Rick Majerus while the head coach at Cardinal Stritch, preparing a game plan for his Division 2 team to play a Division 1 opponent, what he thinks of the current edition of the Billikens,, and last but not least Chris Sloan's eating habits.

This week: Our correspondent Chris Sloan on Jet Blue's inaugural London flight; Delta's insurance surcharge for unvaccinated employees; Arrivederci to Alitalia; Southwest cuts 27 flights; British Air launching a low cost carrier. Next week: We celebrate episode #100!

This week: Chris Sloan talks Ghost Airports (Boo!); The Spirit operational meltdown; Copa Airlines Q2 results & competitive advantages; United's Scott Kirby announces 100% employee vaccine requirement; The Frontier duct tape passenger take-down. Plus listener questions and shout-outs.

In this Meet the Pros episode, green industry pro https://sloanslawncare.com/ (Chris Sloan of Sloan's Lawncare LLC )talks about what motivated him to start his business, how he maintains a healthy working relationship with his wife, and his best tips and tricks he'd give to other green pros. Connect with us online: https://echomeansbusiness.com/ (Visit us at ECHO Means Business) https://www.echomeansbusiness.com/pages/emb-mobile-app (Download our mobile app) https://www.instagram.com/echo.meansbusiness/ (Follow us on Instagram) https://www.youtube.com/channel/UC3_dtdhrJqS1thoH5WhK07Q (Watch us on YouTube) https://www.facebook.com/echomeansbusiness/ (Like us on Facebook) Connect with Chris: https://www.instagram.com/mrgrassgrind/ (Instagram) https://www.youtube.com/channel/UC3MCCpnfz5omWHOZO5J2vFQ (YouTube)

Join us as we continue in our summer series, "One," where we have been getting the opportunity to hear from different guest speakers and grow in faith. One is a series where we can look forward to receiving from many voices the one cohesive message God has given the church.PRAYER:Text "FATHOM" to 97000 if you'd like a member of our prayer team to pray with or for you.NEXT STEPS:Are you ready to learn more about what it means to walk with Christ, get baptized, or get connected within the church body? Click here to complete our digital connect card: https://fathom.churchcenter.com/people/forms/31883GOT QUESTIONS?Learn more about Fathom Church at http://fathom.church/ or email us at info@fathom.churchWE'RE HERE FOR YOU!If you're looking for more encouragement and biblical teaching throughout the week, we hope you'll download the Churchcenter app for access to our archive of Sunday Sermons, or check out past episodes of our Fathom Beyond Sunday Podcast (currently on break for the summer months) here: http://fathom.church/category/listen/

This week: General Counsel & Secretary of the Flight Safety Foundation & top ranked aviation lawyer Ken Quinn; The Belarus hijacking of a Ryan Air flight;Our roving reporter Chris Sloan reviews the inaugural flight of Breeze. A Southwest complaint-Fine? or Whine? Listener questions & shout-outs.

In the third part of this networking series green industry professionals https://www.facebook.com/AJslawncaretx/ (Teno Cardos of AJ's Lawn Care), https://www.instagram.com/jc_thelawncareguy/ (Jensen Martinez "JC" of Lawn Squad Mowing ),http://www.bedellpropertymanagement.com/ (Mike Bedell of Bedell Property Management LLC,) https://sloanslawncare.com/ (Chris Sloan of Sloan's Lawncare LLC), and http://www.currivangreen.com/ (Josh Currivan of Currivan Green Co, Inc) discuss a variety of tips and strategies to help budget your business to help ensure its profitability. The topics on the show today include:  How to charge for your services to ensure you turn a profit Why should you change your pricing from year to year The importance of budgeting and tips on how to budget your business Why your price is unique to your business and situation What mistakes you will make in your first year How to determine your overhead cost How much money do you put away How to budget for future growth What software to use for budgeting? When do you say NO? How to qualify customers How to price – seasonal vs. annual  How to establish your business The use of contracts The importance of looking at your personal budget and expenses Connect with us online: https://echomeansbusiness.com/ (Visit us at ECHO Means Business) https://www.echomeansbusiness.com/pages/emb-mobile-app (Download our mobile app) https://www.instagram.com/echo.meansbusiness/ (Follow us on Instagram) https://www.youtube.com/channel/UC3_dtdhrJqS1thoH5WhK07Q (Watch us on YouTube) https://www.facebook.com/echomeansbusiness/ (Like us on Facebook) Connect With Teno: https://www.facebook.com/AJslawncaretx/ (Facebook) https://www.instagram.com/tenowithajslawncare/ (Instagram) Connect With Jensen: https://www.instagram.com/jc_thelawncareguy/ (Instagram) https://www.youtube.com/channel/UC7Kt8jzEx6veoG1BCSn9Shw (Youtube) Connect With Michael: https://www.facebook.com/bedellmgmt (Facebook) https://www.instagram.com/bedellmgmt/ (Instagram) https://twitter.com/bedellmgmt (Twitter) https://www.youtube.com/channel/UCj5lIIEfHw1BHWKoLnEZh0Q (Youtube) Connect With Chris: https://www.instagram.com/mrgrassgrind/ (Instagram) https://www.youtube.com/channel/UC3MCCpnfz5omWHOZO5J2vFQ (Youtube) Connect with Josh: https://anchor.fm/thewescapepodcast (The WeScape Podcast) https://www.instagram.com/jaycurri/ (Instagram) https://www.youtube.com/channel/UC4cpy1Z5wz2IvgYY35Qd75g (YouTube) https://www.facebook.com/Currivangreenlandscaping/ (Facebook)

Airbus has a winner with the A220, and airlines are just starting to discover what they can do with the aircraft’s size and range. Chris Sloan, publisher of theairchive.net joins for a discussion on the A220 and the Boeing 737 Max. 

Scott, Craig & Kyle are back to start 2021 off with the first episode of Season 2. Chris Sloan is our guest and friend for many years. Scott & Chris talk about the first time they met over lunch at Arby's. Chris shares his story of finding Jesus as a college student and his passion to combat hunger in the greater Spokane area. Show Notes: At The Core (Chris' non-profit he started with his wife) Bite2Go Program Bible Project Reading Plan Bible Project The Find & Follow format is simple. It's real people having an unscripted conversation about life and Jesus every week and the seasons are made. Life is in the Light.... Spiritual darkness is the enemy... and Finding and Following Jesus is the best way to live your life! www.mc.life/podcast

Alex Azar, who is the current Health and Human Services (HHS) secretary (until January 21 anyway), came out with a reboot of the proposal that effectively halts the practice of pharma manufacturers paying rebates to Part D plans. This reboot is supposed to go into effect on 1/1/2022. But this podcast is less about this may-or-may-not-actually-happen rule and is more about the actual impact of removing drug rebates within this unintuitively constructed health care system of ours. Should rebates go away, it’s actually a big deal that fundamentally could upend the heretofore-not-transparent messy middle of drug pricing. I’ll let Chris Sloan, associate principal over at Avalere Health, explain. Spoiler alert: The impact of killing pharma rebates to plans and PBMs (pharmacy benefit managers)? Bottom line, everybody’s insurance premiums go up in the current model when rebates go away. A few episodes from now, I’m talking with Ge Bai about why this is a suboptimal and not forgone conclusion. But this is what we’ve got going on right now. So, look for EP306 coming up for more on that. You can learn more at avalere.com.   Chris Sloan, associate principal at Avalere, advises a number of clients—including pharmaceutical manufacturers, health plans, providers, and patient groups—on key policy issues facing the health care industry. Chris’s economic analyses of key policy proposals and issues, including drug pricing and the repeal and replace efforts around the Affordable Care Act, have been featured in a wide range of publications, including the Wall Street Journal, the New York Times, the Washington Post, Politico, Axios, and Vox. 02:35 “Rebates are a really big part of Medicare Part D.” 02:49 What the “follow the dollar” looks like in this scenario. 04:14 How rebates between PBMs and manufacturers work, and how list prices play into this. 05:31 How this system can hurt the patient, and how this new proposal works to change that. 06:42 Pricing a product as a PBM. 08:06 The total dollar value of PBM rebates. 10:50 Do we know how much PBMs are making in incentives? 13:29 Are PBMs helping or hurting the process? 16:18 Why pharmaceutical manufacturers may be more compelled to raise their prices thanks to large PBMs. 17:13 Perverse incentives in the system. 17:57 “At the end of the day, PBMs are still going to be employed by health plans.” 18:56 How a new model is combating the perverse incentive that raises prices for patients. 22:11 The trade-off involving premium prices in this new proposal. 24:38 “We’re not talking astoundingly large amounts of money.” 25:12 Why PBMs and health plans are against this proposal. 26:02 Why Pharma is for this. 26:51 The perverse incentives for health plans. 28:39 The benefit of Part D. 29:25 The advantage of huge rebates. You can learn more at avalere.com.   @avalerechris discusses eliminated #drugrebates in this week’s #healthcarepodcast. #healthcare #podcast #digitalhealth #pharma “Rebates are a really big part of Medicare Part D.” @avalerechris discusses eliminated #drugrebates in this week’s #healthcarepodcast. #healthcare #podcast #digitalhealth #pharma What does following the dollar really look like? @avalerechris discusses eliminated #drugrebates in this week’s #healthcarepodcast. #healthcare #podcast #digitalhealth #pharma Do we know how much #PBMs are making in incentives? @avalerechris discusses eliminated #drugrebates in this week’s #healthcarepodcast. #healthcare #podcast #digitalhealth #pharma Are #PBMs helping or hurting the process? @avalerechris discusses eliminated #drugrebates in this week’s #healthcarepodcast. #healthcare #podcast #digitalhealth #pharma “At the end of the day, PBMs are still going to be employed by health plans.” @avalerechris discusses eliminated #drugrebates in this week’s #healthcarepodcast. #healthcare #podcast #digitalhealth #pharma “We’re not talking astoundingly large amounts of money.” @avalerechris discusses eliminated #drugrebates in this week’s #healthcarepodcast. #healthcare #podcast #digitalhealth #pharma

This week: Special guest Chris Sloan from The Airchive; The 737-Max takes flight again. How will people feel about flying on it? Why does Delta have multiple Midwest hubs? What's the business structure of airline alliances? and Seth has a complaint about Spirit...is it Fine? or a Whine?

Welcome Aboard The Airways Podcast! In this second episode of Season 4, Rohan, Vinay, and Enrique jump right into three very interesting topics:  • Singapore Airlines to retire some Airbus A380s and Boeing 777-300s. • Air Canada cancels some Airbus A220s and Boeing 737 MAX orders. • Alaska Airlines names new CEO (bonus: fleet discussion) • The Top 5 most-read news on Airwaysmag.com And in this episode, we welcome Chris Sloan, founder of The Airchive, who shares with Rohan the details of the re-launch of his "webseum" of Aviation. Stay tuned, The Airways Podcast is here!

Today's guest is Chris Sloan, the Chief Operating Officer of Capital Medical Center in Olympia, Washington. Capital Medical Center is a 107-bed hospital with about 600 employees. It is part of LifePoint Health, a for-profit hospital system headquartered in Brentwood, Tennessee. Chris joined Capital Medical Center after retiring from the Army Medical Service Corps in September of 2019, with 23 years of service as a military medical logistician and hospital administrator. During his service he deployed to Kosovo and Iraq, and ended his career as the Chief Operating Officer for Madigan Army Medical Center, one of the Army's largest hospitals. In this podcast we talk about Chris's military career, transition to leadership in the civilian sector, his leadership philosophy, and, since this interview was originally recorded in October of 2020, the impact of the COVID-19 pandemic. for more information, please see our website: http://healthleaderforge.org

Today's guest is Chris Sloan, the Chief Operating Officer of Capital Medical Center in Olympia, Washington. Capital Medical Center is a 107-bed hospital with about 600 employees. It is part of LifePoint Health, a for-profit hospital system headquartered in Brentwood, Tennessee. Chris joined Capital Medical Center after retiring from the Army Medical Service Corps in September of 2019, with 23 years of service as a military medical logistician and hospital administrator. During his service he deployed to Kosovo and Iraq, and ended his career as the Chief Operating Officer for Madigan Army Medical Center, one of the Army's largest hospitals. In this podcast we talk about Chris's military career, transition to leadership in the civilian sector, his leadership philosophy, and, since this interview was originally recorded in October of 2020, the impact of the COVID-19 pandemic. For more information, see our website: http://healthleaderforge.org

I am so excited this week to have the Chris & Berna Sloan on the podcast. Chris Sloan is on the Foundations Board of Directors. This week, Berna Sloan will share her story. Her purpose for sharing her story of adverse childhood experiences, is to bring hope to the listener, that your past does not define your future. That there is no limit to what you can become. That you can break the chain of abuse and have a bright tomorrow. Berna is a living example of success. I am so grateful for her coming on the show, and willing to be vulnerable to help others along their journey.

Disclaimer before we get started here: This show is probably a 300-level class in pharmaceutical/PBM relations. If you are tuning in for the first time and you aren’t pretty familiar with the role of PBMs, I would go back and listen to, say, episode 241 with Vinay Patel or episode 166 with Tim Thomas from Crystal Clear Rx.  OK, now that that’s out of the way, if you’re still with me, this episode is like a ride on a roller coaster. In this health care podcast, I talk with Mike Schneider, who’s a principal over at Avalere Health. And we get into, you know, kinda deeply, the what and the why behind the "Big Three" traditional PBMs deciding that now might be a fantastic time to set up GPOs. PBMs are pharmacy benefit managers—there’s three huge ones. GPO stands for group purchasing organization. Traditionally, these GPOs have purchased drugs and supplies for hospitals and other providers at, according to their marketing materials, volume discounts. So, the unfolding story here, in a nutshell, is that ESI (Express Scripts) set up a GPO called Ascent in Switzerland. Optum has had an Ireland operation going in full swing for a while. And now we have CVS Caremark setting up a GPO called Zinc. These GPOs are not like normal GPOs working with hospitals, but instead, these GPOs are the entity which is now going to negotiate with pharma companies. In the past, it was the PBM that was negotiating with the pharma company to get rebates. Now it’s this GPO entity. “But wait,” you may say. “Wasn’t there an executive order the other day requiring PBMs to, for example, pass through all of the rebates that they’re collecting to patients?” Indeed, there was. And that rule doesn’t say anything about GPOs having to do the same, especially GPOs in, let’s just say, Switzerland. It’s a tangled web we weave. You can learn more at avalere.com. You can also connect with Mike on LinkedIn.  Mike Schneider is an experienced health care executive with over 20 years of experience in the pharmaceutical manufacturer, pharmacy benefit manager, and payer side of health care. He previously spent 9 years at CVS Caremark, where he was a director of industry relations with responsibility for trade strategy development, rebate negotiations, and contract execution for CVS Caremark’s own Medicare Part D plans and that of its clients. He held a similar position at Universal American (UA) before it was acquired by CVS Health, where he also negotiated UA’s commercial business. Mike has held various sales and market access roles with pharmaceutical manufacturers with increasing responsibility. Before entering health care, Mike began his career as a researcher at the Procter & Gamble Company in Cincinnati, where he worked on hair care product formulation development focusing on the key markets of China and Japan, and then moved on to work in drug development. Mike holds a BS degree from the University of Illinois and an MBA from the University of Akron. 02:30 What does a GPO add to a PBM? 05:05 Rebates vs driving more revenue. 10:20 PBMs vs safe harbors. 12:07 The net impact on the commercial side. 13:48 PBMs vs pharmaceutical manufacturers. 14:35 How the "Big Three" PBMs compete with each other, and how employers would choose between them. 15:37 What the net-net is here. 17:48 How PBMs are shifting their models. 20:23 How GPOs may be making things even less transparent. 21:11 “The PBM world as a whole is not very transparent.” 24:40 “One of the biggest beneficiaries of this whole rebate [system] is the government.” 25:25 “The question is, ‘Who’s paying those costs?’” 25:40 EP216 with Chris Sloan.26:40 A better way to move money from Pharma to employers and plan sponsors. 27:43 “Put your money where your mouth is.” You can learn more at avalere.com. You can also connect with Mike on LinkedIn.  Check out our newest #healthcarepodcast with Mike Schneider of @avalerehealth as he discusses #PBMs and #GPOs. #healthcare #podcast #digitalhealth #healthcarefinance #pharma What does a GPO add to a PBM? Mike Schneider of @avalerehealth discusses #PBMs and #GPOs. #healthcarepodcast #healthcare #podcast #digitalhealth #healthcarefinance #pharma Rebates vs driving more revenue. Mike Schneider of @avalerehealth discusses #PBMs and #GPOs. #healthcarepodcast #healthcare #podcast #digitalhealth #healthcarefinance #pharma PBMs vs safe harbors. Mike Schneider of @avalerehealth discusses #PBMs and #GPOs. #healthcarepodcast #healthcare #podcast #digitalhealth #healthcarefinance #pharma What is the net impact on the commercial side? Mike Schneider of @avalerehealth discusses #PBMs and #GPOs. #healthcarepodcast #healthcare #podcast #digitalhealth #healthcarefinance #pharma PBMs vs pharmaceutical manufacturers. Mike Schneider of @avalerehealth discusses #PBMs and #GPOs. #healthcarepodcast #healthcare #podcast #digitalhealth #healthcarefinance #pharma How do the "Big Three" PBMs compete with each other? Mike Schneider of @avalerehealth discusses #PBMs and #GPOs. #healthcarepodcast #healthcare #podcast #digitalhealth #healthcarefinance #pharma How do #employers choose between the "Big Three" PBMs? Mike Schneider of @avalerehealth discusses #PBMs and #GPOs. #healthcarepodcast #healthcare #podcast #digitalhealth #healthcarefinance #pharma What’s the net-net here? Mike Schneider of @avalerehealth discusses #PBMs and #GPOs. #healthcarepodcast #healthcare #podcast #digitalhealth #healthcarefinance #pharma How are PBMs shifting their revenue models? Mike Schneider of @avalerehealth discusses #PBMs and #GPOs. #healthcarepodcast #healthcare #podcast #digitalhealth #healthcarefinance #pharma How are GPOs making things even less transparent? Mike Schneider of @avalerehealth discusses #PBMs and #GPOs. #healthcarepodcast #healthcare #podcast #digitalhealth #healthcarefinance #pharma “The PBM world as a whole is not very transparent.” Mike Schneider of @avalerehealth discusses #PBMs and #GPOs. #healthcarepodcast #healthcare #podcast #digitalhealth #healthcarefinance #pharma “One of the biggest beneficiaries of this whole rebate [system] is the government.” Mike Schneider of @avalerehealth discusses #PBMs and #GPOs. #healthcarepodcast #healthcare #podcast #digitalhealth #healthcarefinance #pharma “The question is, ‘Who’s paying those costs?’” Mike Schneider of @avalerehealth discusses #PBMs and #GPOs. #healthcarepodcast #healthcare #podcast #digitalhealth #healthcarefinance #pharma A better way to move money from Pharma to employers and plan sponsors. Mike Schneider of @avalerehealth discusses #PBMs and #GPOs. #healthcarepodcast #healthcare #podcast #digitalhealth #healthcarefinance #pharma “Put your money where your mouth is.” Mike Schneider of @avalerehealth discusses #PBMs and #GPOs. #healthcarepodcast #healthcare #podcast #digitalhealth #healthcarefinance #pharma

Chris Sloan of Baseline partners shares more about private credit and how this asset class has unique characteristics to assist a portfolio.

Welcome Aboard The Airways Podcast! The 53rd episode of the show starts with Rohan Anand, Vinay Bhaskara, and Enrique Perrella chatting about how the COVID-19 pandemic continues to affect the world's airlines, focusing on Avianca, Colombia's flag carrier, which just filed for Chapter 11. The next segment of this episode welcomes our Senior Correspondent, Chris Sloan, who jumped on a phone call with Gordon Bethune, a retired US airline executive who was the CEO of Continental Airlines from 1994 until his retirement at the end of 2004. Bethune weighs in and shares his thoughts on the current state of the aviation industry and shares some comments on Boeing and the extended crisis it's been mitigating. This episode closes with a different approach: Vinay and Rohan ask Enrique which are his favorite aircraft, airline, and airport, entering into an entertaining AvGeek debate. As the world continues to battle COVID-19, the Airways Team hopes you will enjoy this episode. Tune in, The Airways Podcast is here!

Former Billiken Chris Sloan joins the podcast for a three plus hour conversation about his time at SLU and adds in some great stories.

Ghost of Tsushima (finally) gets a release date, a new Amnesia game is announced and The Last of Us gets a big-budget HBO series- leading us to discuss who we would love to see play Joel. This week we also introduce our new segment ‘This week InDreams…’ in which we highlight an excellent creation from Media Molecule’s Dreams. Our main topic is the Final Fantasy 7 Remake demo which causes a new level of hype and excitement (if that was possible…). Finally, listen out for two free pieces of wisdom from Bomb Squad’s own Chris Sloan. We discuss what we would like to see from the PS5 as well as getting into an incredibly in-depth discussion about Pokemon!

Welcome Aboard The Airways Podcast! The 48th episode starts off with our hosts discussing the importance and threat of the current Coronavirus outbreak, which is causing endless trouble on the worldwide commercial aviation scene. Rohan's trip to India ignites Vinay's fears, diving into an initial discussion that will carry on in our next episode with invited experts. Stay tuned! Our first analysis segment in this episode features Vinay and Rohan chatting about David Neeleman's newest airline startup, Breeze Airways. Is this airline set on a successful business plan? Neeleman, who successfully launched and developed Morris Air, WestJet, JetBlue, Azul, and transformed TAP Portugal into a healthy carrier, is now re-entering the highly competitive US market with an all-new low-cost carrier. Breeze’s initial markets will be mid-size city pairs that currently have no nonstop service, all served with low-fare, high-quality nonstop flights that will bring “new consumer technology innovations, according to Neeleman. Secondly, this episode features a long interview with Airways Senior Correspondent, Chris Sloan, who witnessed the first flight of the Boeing 777-X. In his long conversation with Rohan, Sloan dives into the event's behind-the-scenes and analyzes Boeing's current and future strategy to put this aircraft in service. Lastly, our hosts discuss the goods and the bads from the commercial aviation scene and conclude this episode with a few personal remarks on the Coronavirus trending topic. Tune in, The Airways Podcast is here!

Welcome Aboard The Airways Podcast! The fifth episode of Season 3 kicks off with Rohan, Vinay, and Enrique chatting about Air New Zealand's exciting news, which will see the Kiwi carrier link Auckland and New York on an ultra-long-haul nonstop flight on its Boeing 787-9 Dreamliner. This will be the sixth-longest flight in the world when it launches next year. The second segment has Rohan and Vinay interviewing Chris Sloan, Managing Editor at Airways, who was lucky enough to be onboard the farewell American Airlines MD-80 flight.  Tune in, The Airways Podcast is here!

In an increasingly diversified video content distribution sphere with more and more OTT channels joining the frenzy, keeping oversight can be challenging. Where is it all going and what does it mean for traditional broadcast? Chris Sloan takes a stab at it.

Welcome Aboard The Airways Podcast! The second episode of Season 3 kicks off with Rohan Anand, Vinay Bhaskara and Enrique Perrella going over the most relevant headlines in the commercial aviation industry since this month's Episode 1, two weeks before. In this episode, in the second part of our exclusive interview with David Neeleman he tells Airways Managing Editor, Chris Sloan, his thoughts on the ultra-long-haul segment of the industry, the A321XLR, what he thinks about his involvement with TAP Portugal, and a few personal remarks. Our three hosts also analyze three topics drawn from the top headlines in the commercial aviation scene: American Airlines retires the MD-80 from its fleet. British Airways is crippled by two days of flight crew strikes. Frontier opens new base in Newark with all-new routes. Tune in, The Airways Podcast is here!

Welcome Aboard The Airways Podcast! Season 3 kicks off with an all-new format. Rohan Anand and Vinay Bhaskara welcome Enrique Perrella as the third host of the show. Enrique, the Publisher & Editor in Chief of Airways Magazine, also joins the production team, bringing in numerous guests from the industry to be featured in this season's interview segment. This new season will be edited and cured by our new team member, Jeffry Nova, a professional radio veteran who's taking The Airways Podcast to a new level of quality. In this episode, David Neeleman exclusively tells Airways Managing Editor, Chris Sloan, the tentative launch date of his new startup, code-named Moxy. Rohan, Vinay, and Enrique analyze three topics drawn from the top headlines in the commercial aviation scene: Boeing mothballs the launching of the 777-8X. Cathay Pacific changes its top management. Tokyo-Narita gives way to Haneda as the prime airport for US carriers. Tune in, The Airways Podcast is here!

If you don’t know the nuts and bolts of the current Health and Human Services (HHS) proposal to nix Pharma’s ability to pay pharmacy benefit manager (PBM) rebates, then it’s possible you might want to listen to EP216 with Chris Sloan first. In this episode, we don’t talk much about the impact of the HHS proposal on patient premiums or drug costs. That’s EP216. What we do talk about today is the impact on pharmaceutical companies. We also discuss the drug-buying transaction. Kuo Tong is my guest today. Kuo is a managing director in the life sciences practice of Navigant, focusing on how pharma companies interact with insurance companies and get reimbursement for their drugs. And that’s actually the burning question we aim to answer today: Will Pharma’s interactions with and reimbursement from insurance companies change after this proposed HHS rule goes into effect, assuming it goes into effect? We also talk about what Pharma could and should be doing right now to improve the odds of a smooth transition into a new contracting model.   You can learn more at navigant.com, connect with Kuo on Twitter at @NavigantHealth, or email him at kuo.tong@navigant.com. Kuo Tong is a managing director in the life sciences practice of Navigant and oversees its US Market Access Center of Excellence. He joined the firm in November 2017 to lead a team focused on health economics, pricing, and market access engagements. Prior to joining Navigant, Kuo was the CEO of Quorum Consulting, headquartered in San Francisco, for 21 years. During that time, Quorum was a leading firm helping clients solving policy and access issues with the Centers for Medicare & Medicaid Services (CMS); Blue Cross Blue Shield, commercial, and managed care plans; and other payers and health care delivery systems. Prior to founding Quorum, Kuo was a senior associate at Health Technology Associates (now known as Covance), located in Washington, DC. Prior to entering the consulting field, Kuo was active in clinical and health services research at the University of Pennsylvania School of Medicine and the University of California, Los Angeles (UCLA) Neuropsychiatric Institute. Kuo holds his master’s degree from Johns Hopkins University and a bachelor’s degree from the University of Pennsylvania. 01:54 HHS and better market results as far as Pharma is concerned. 02:56 “Entitlement benefit.” 03:49 How would justifying pharma prices change company behavior? 05:47 “Get back to the business of innovation.” 06:13 Sacrificing broad indications for narrow ones. 08:14 “Branded Pharma raises the price of their branded product ahead of competition.” 08:44 “We’re playing by the rules of the road.” 09:09 “I think we have to … start thinking about a new world order.” 09:34 High-valuation dropping and other trade-offs for a better business model. 10:23 How do you make life science purchasing a win-win? 12:42 Pay to play, PBMs, and short-term vs long-term pharma solutions. 17:15 Are specialty drugs and rare disease drugs the future of Pharma? 17:58 Medicare Part D and Medicaid benefits. 23:50 “The Part D plan itself … for better or worse, they are not the advocate for the patient.” 25:00 Could other contracting models be on the rise? 29:23 What Navigant Health does and what Kuo does over at Navigant Health. You can learn more at navigant.com, connect with Kuo on Twitter at @NavigantHealth, or email him at kuo.tong@navigant.com.

Chris Sloan is an associate principal at Avalere Health, a Washington, DC–based nonpartisan consulting firm. He advises a number of clients—including pharmaceutical manufacturers, health plans, providers, and patient groups—on key policy issues facing the health care industry. His particular areas of expertise include drug pricing, the Affordable Care Act, generics, and biosimilars. Additionally, Chris is a recognized expert in the health care policy issues facing people living with HIV/AIDS and multiple sclerosis. Chris’s economic analyses of key policy proposals and issues, including drug pricing and the repeal and replace efforts around the Affordable Care Act, have been featured in a wide range of publications such as the Wall Street Journal, the New York Times, Politico, Vox, and others. He has a BBA degree in economics and marketing from the College of William and Mary. 01:12 The HHS proposal. 02:29 “Rebates are a really big part of Medicaid Part D.” 02:45 What the “follow the dollar” looks like in this scenario. 04:10 How rebates between PBMs and manufacturers work, and how list prices play into this. 05:26 How this system can hurt the patient, and how this new proposal works to change that. 06:37 Pricing a product as a PBM. 08:04 The total dollar value of PBM rebates. 11:24 Do we know how much PBMs are making in incentives? 14:08 Are PBMs helping or hurting the process? 17:13 Why pharmaceutical managers may be more compelled to raise their prices thanks to large PBMs. 18:10 Perverse incentives in the system. 18:55 “At the end of the day, PBMs are still going to be employed by health plans.” 20:29 How a new model is combating the perverse incentive that raises prices for patients. 23:45 The trade-off involving premium prices in this new proposal. 26:13 “We’re not talking astoundingly large amounts of money.” 26:46 Why PBMs and health plans are against this proposal. 27:37 Why Pharma is for this. 29:11 The perverse incentives for health plans. 31:00 The benefit of Part D. 31:46 The advantage of huge rebates.

Chris Sloan's philosophy on law is very much aligned with Poe Group Advisors' experience in helping clients with the purchase and sale of CPA firms. Learn how a concise contract can save you time, money and frustration on both sides of the agreement without sacrificing legal protection.

For the inaugural ANA Government Relations & Legal Podcast, ANA General Counsel, Doug Wood of Reed Smith LLP interviews Chris Sloan, Assistant Vice President & Senior Corporate Counsel at Liberty Mutual on their partnership with USOC and other pressing issues facing advertising legal counsel.

Troubadours & Raconteurs, twenty-five for forty-five? We have for your listening pleasure Episode 254 of "Troubadours and Raconteurs with E.W. Conundrum Demure" Heard All Over The World. Episode 254 features a conversation with Gavin Esham - theatrical writer, performer, director, and half of the stage team known as Gavin & Chris. Gavin and I discuss How He Ended Up in Theater, How He Got Together with Chris Sloan to Start Crafting Shows, We discuss their Upcoming March Production titled "Chris & Gavin's Broadway Campaign Spectacular, LGBTQ Rights, Live and Let Live, Hooker Songs, Thinking & Acting Locally... Episode 254's sixty minutes includes an EW Essay titled "Pop Cult." Our Associate Producer Dr. Michael Pavese shares an excerpt from Tennessee Williams' masterpiece "A Street Car Named Desire." We have a poem called "Untold." Our music this go round is provided by these wonderful artists: Django Reinhardt, Stephan Grapelli, A Tribe Called Quest, the Cast of Toronto's 1993 Showboat Revival, Liza Minelli, Alex North, Jack Black and the Polka King Band, Branford Marsalis and Terrence Blanchard. Commercial Free, Community Radio at its Finest. Share this episode with whomever you choose. Tell your Friends and Neighbors... Become a friend via facebook - Freespeakandsome Withewconundrum. Follow us on Twitter @FreespeakWit. Email us ewconundrum@radiofreebrooklyn.org

This is an election year for the ages. The rhetoric is at a fevered pitch, the sides are divided, and the issues muddied by inaccuracies, half-truths, lies, and innuendo. How do we help our students wade through the messages, see the purpose in participating, and become actively engaged with the presidential election? Find out during this lively conversation with high school teachers Janelle Bence of Texas and Chris Sloan of Utah, two teachers who are making the election a focal part of their work this fall.

Executive director Chris Sloan is back to discuss all of the exciting fall art events happening at the Art's Council and the Artist Studio Tour in October.  Each event is free and open to the public and creates an opportunity to bring the world of art to our area.  For more information on the events please click on the links provided below.  September 10th is the ArtsWalk   The New Normal Opening   October 22-23 and 29-30 is the Artist Studio Tour 

In Episode 1 of the Airways Podcast, Vinay Bhaskara, Rohan Anand, Chris Sloan, and Austin Speaker tackle the Bombardier CSeries, United Airlines' new business class, and the coveted daytime slots at Tokyo's Haneda Airport.

As part of a special series designed for the Letters to the Next President 2.0 project, this kickoff “Media Make” features educators Janelle Bence and Chris Sloan leading a conversation with students and other teachers about developing and discussing diverse political views in the classroom during a particularly contentious election. Watch the full hangout at: http://educatorinnovator.org/webinars/developing-and-discussing-diverse-political-views-in-the-classroom-and-beyond/ Learn more about L2P 2.0 at: http://letters2president.org/

Mr. Sloan is chair of the Firm's Emerging Companies Group and focuses his practice on start-ups and other emerging businesses and also handles complex software and other IT transactions for both small and large companies alike. He helps many early-stage, high-growth businesses with business planning and formation, venture capital funding, drafting and negotiating vendor and customer agreements, strategic contract negotiations, mergers and acquisitions, intellectual property protection and other general business law and intellectual property law issues. He often serves as outside general counsel for these types of companies.  Mr. Sloan regularly represents both technology and brick-and-mortar clients in connection with software, IT and other vendor contract negotiations, including software and health care IT transactions valued as high as $100 million. He regularly counsels hospitals and other health care providers on IT and intellectual property issues. Mr. Sloan takes pride in providing his clients with practical, cost-effective advice tailored for each client's unique business objectives. He is actively involved in the technology and entrepreneur communities, and he is a frequent author, speaker, board member and leader in that community.   He is actively involved in the Nashville Technology Council and currently serves as general counsel. Mr. Sloan was a member of the Nashville Chamber's Partnership 2010 Entrepreneurship Task Force and serves on the advisory board for the Nashville Entrepreneur Center. Mr. Sloan is a long-standing member of the executive committee of the Tennessee Bar Association's Intellectual Property Law Committee.    

Join Matthew Green and Matt Williams of KQED, along with Chris Sloan of the Wasatch Range Writing Project and Kirsten Spall of the Area 3 Writing Project, as they discuss the various dimensions of Newsroom to Classroom, a pilot project in which pairs of NWP teachers from around the country develop resources and curriculum packages that focus on news topics. You can also hear a student perspective on this opportunity to use digital tools to weigh in on the issues of our times.

Academy of Art University Presents National Geographic with Chris Sloan.

This show introduces Youth Voices, a customized school-based social network started by a group of National Writing Project teachers. We visit with Paul Allison, Chris Sloan, Carla Cherry, and Jim Nordlinger who use Youth Voices with their own students and focus on both the possibilities of and resources for supporting interest-driven writing in connected ways.

1999-10-19 Methyl Cyclo-PentaneSnotty, Benny C, Sara, Stella, Dave Ludt, Amy, Sloan, Farrugia, Jamie Austin, others 3:04:14Doggy dogg intro with Benny C and Snotty intro. Define Respect. Do you believe me now? Quick lowdown to all you folks that don't know. It is Monday. It's only the beginning of the week. Pull up a chair and sit down and relax because yeah. Chris Sloan calls in, he's the man. Pokey gets a well deserved night off so we got Methyl Cyclo-Pentane filling in, and answering the phone. Thank you. We call up Farrugia for a 1 O'clock Report. Sickness has invaded. Yankees to the Series. Good night Stella. Ladies and gentlemen Dave Ludt and thus the Radio Torture was born. I bet no one is listening. There is at least someone listening. Playing with the Station IDs. I need some Pants. Quick shot out to Mike Love. Is it SUCO or SUNY Oneonta? Anyone seen Steve?1999-10-19 | 3:04:14 | 2BS Radio Archive | The Main Event | Monday (actually Tuesday) | Midnight to 3AM | WRHO 89.7 FM Hartwick College Oneonta NY | The B-Smith Radio Archive | Archived Recordings from my College Radio Show | www.twobs.com | 2bsradioarchive.blogspot.com | For full details > http://twobs.com/wiki/2BS_Radio_Archive_1999-10-19